The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma
(MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we …

In a translational relevant transcriptomic-based classification, we characterized the
microenvironment as a critical component of the B-cell lymphoma biology and associated it with the …

Given the frequent and largely incurable occurrence of multiple myeloma, identification of
germline genetic mutations that predispose cells to multiple myeloma may provide insight into …

Selected patients with brain metastases (BM) are candidates for radiotherapy. A lactatogenic
metabolism, common in BM, has been associated with radioresistance. We demonstrated …

Methyl-7-guanosine (m 7 G) “capping” of coding and some noncoding RNAs is critical for
their maturation and subsequent activity. Here, we discovered that eukaryotic translation …

Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin
Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of …

Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large
B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance…

The oncogenic form of HSP90 organizes and maintains functional multienzymatic metabolic
hubs in cancer cells, suggesting the potential of repurposing oncogenic HSP90 selective …

XPO1 regulates the dynamic ribonucleoprotein nuclear export in response to genotoxic
stress to support tolerance and can be targeted to enhance the sensitivity of cancer cells to …

Peripheral T-cell lymphomas (PTCL) with T-follicular helper phenotype (PTCL-TFH) has
recurrent mutations affecting epigenetic regulators, which may contribute to aberrant DNA …